Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.8 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

Paratek Pharmaceuticals and Zai Lab Announce Collaboration, Development and License Agreement for Omadacycline in China

April 24, 2017
BOSTON, April 24, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today announced that…

Verona Pharma Receives Authorization from the U.S. FDA to Proceed with Clinical Investigation of RPL554 with the Acceptance of Investigational New Drug Application

April 18, 2017
18 April 2017, London – Verona Pharma plc (AIM: VRP) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of…

Syros Announces FDA Acceptance of IND to Advance SY-1365, its First-in-Class Selective CDK7 Inhibitor, into Phase 1 Clinical Trial in Patients with Advanced Solid Tumors

April 10, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 10, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, announced today that the…